Patents by Inventor Jon C. Aster

Jon C. Aster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antigen-Presenting Neutrophil-Derived Dendritic Cells and Methods of Use Thereof
    Publication number: 20220106566
    Abstract: Methods and compositions for use in generating or promoting an immune response to cancer or an infection, comprising promoting differentiation of neutrophils into dendritic cells using a combination of GMCSF and (i) an immune complex comprising an antigen and an antibody comprising an Fc region that binds to Fc?RIIA or Fc?RIIIB, (ii) a conjugate comprising an antigen and an anti-Fc?RIIIB antibody, or (iii) an anti-Fc?RIIIB antibody.
    Type: Application
    Filed: January 22, 2020
    Publication date: April 7, 2022
    Inventors: Tanya Mayadas, Vijaya Mysore, Xavier Cullere, Jon C. Aster
  • Diagnostic and treatment methods in subjects having or at risk of developing resistance to cancer therapy
    Patent number: 9763956
    Abstract: The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: September 19, 2017
    Assignees: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc., The General Hospital Corporation, Dana-Farber Cancer Institute, Inc.
    Inventors: Bradley E. Bernstein, Jon C. Aster, James E. Bradner, Birgit Knoechel, Christopher J. Ott, David Root
  • In vitro culture conditions for T-cell acute lymphoblastic leukemia/lymphoma
    Patent number: 9683217
    Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: June 20, 2017
    Assignees: UNIVERSITY OF MIAMI, The Brigham and Women's Hospital, Inc.
    Inventors: Tan A. Ince, Jon C. Aster
  • DIAGNOSTIC AND TREATMENT METHODS IN SUBJECTS HAVING OR AT RISK OF DEVELOPING RESISTANCE TO CANCER THERAPY
    Publication number: 20150174138
    Abstract: The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.
    Type: Application
    Filed: June 19, 2013
    Publication date: June 25, 2015
    Applicants: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Dana-Farber Cancer Institute, Inc.
    Inventors: Bradley E. Bernstein, Jon C. Aster, James E. Bradner, Birgit Knoechel, Christopher J. Ott, David Root
  • IN VITRO CULTURE CONDITIONS FOR T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA
    Publication number: 20150119557
    Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 30, 2015
    Applicants: THE UNIVERSITY OF MIAMI, THE BRITISH COLUMBIA CANCER AGENCY BRANCH, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Andrew P. Weng, Jon C. Aster, Tan A. Ince
  • NOTCH mutations leading to increased receptor signaling
    Patent number: 8716233
    Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 6, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Jon C. Aster, Stephen C. Blacklow, A. Thomas Look, Adolfo A. Ferrando, Andrew P. Weng
  • NOTCH mutations leading to increased receptor signaling
    Publication number: 20100087358
    Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increase receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.
    Type: Application
    Filed: May 22, 2009
    Publication date: April 8, 2010
    Applicants: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Jon C. Aster, Stephen C. Blacklow, A. Thomas Look, Adolfo A. Ferrando, Andrew P. Weng
  • Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
    Publication number: 20080241150
    Abstract: The present invention relates to a LNR-HD domain of the Notch receptor and methods of use. The method for expression and structural determination of the LNR-HD domain is described.
    Type: Application
    Filed: May 15, 2007
    Publication date: October 2, 2008
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Stephen Blacklow, Didem Vardar-Ulu, Wendy Ryan Gordon, Cheryll Sanchez-Irizarry, Jon C. Aster
  • Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis
    Publication number: 20030194701
    Abstract: Methods for predicting phenotypic classes of lymphomas, such as lymphoma type or treatment outcome, for lymphoma samples based on gene expression profiles are described.
    Type: Application
    Filed: November 20, 2001
    Publication date: October 16, 2003
    Inventors: Todd R. Golub, Pablo Tamayo, Margaret Shipp, Eric S. Lander, Jon C. Aster
  • Modulating lymphoid commitment and survival
    Publication number: 20030181380
    Abstract: Provided are methods for manipulating aspects of lymphopoiesis by modulating and controlling Notch signaling, thereby providing treatment for diseases of the immune system. Accordingly, there are provided methods for selectively modulating T cell fate commitment of a common lymphoid progenitor at the expense of B cell fate commitment, and in the converse for selectively modulating B cell fate commitment of a common lymphoid progenitor at the expense of T cell fate commitment. Also provided are methods for treating patients suffering from a disease or disorder of T cell origin, or conversely of B cell origin. Further provided are methods for selectively killing B cells in a committed population of B cells, such as in a patient suffering from B cell leukemia or lymphoma; as well as methods for selectively killing T cells in a committed population of T cells such as in a patient suffering from diseases of T cell origin.
    Type: Application
    Filed: March 10, 2003
    Publication date: September 25, 2003
    Inventors: Warren S. Pear, David Allman, Yiping He, David J. Izon, Jon C. Aster